An open label study to assess the effect of neoadjuvant treatment with docetaxel + Xeloda + Avastin on pathological response rate in inflammatory or locally advanced breast cancer.

Trial Profile

An open label study to assess the effect of neoadjuvant treatment with docetaxel + Xeloda + Avastin on pathological response rate in inflammatory or locally advanced breast cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Docetaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 17 Jul 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 20 Jan 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 20 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top